Table 2-.
Disease characteristics, treatment and outcomes
| Variable | N(607) | % | |
|---|---|---|---|
|
| |||
| Duration of symptoms (months) | Mean±S.D | 10.10±13.94 | |
| Tumour Size (cm) | Mean±S.D | 10.46±7.76 | |
| Breast Ulceration | Yes | 135 | 22.2 |
| No | 469 | 77.3 | |
| Unknown | 3 | 0.5 | |
| Laterality | Unilateral | 576 | 94.9 |
| Bilateral | 31 | 5.1 | |
| Group Staging | 1 | 7 | 1.2 |
| 2 | 92 | 15.2 | |
| 3 | 369 | 60.8 | |
| 4 | 123 | 20.3 | |
| Missing | 23 | 3.8 | |
| Immunohistochemistry ER Status |
Positive |
N(131) 53 |
% 40.5 |
| Negative | 78 | 59.5 | |
| PR Status | Positive | 42 | 32.1 |
| Negative | 89 | 67.9 | |
| HER 2 Status | Positive | 43 | 32.8 |
| Negative | 88 | 67.1 | |
| Treatment received | Chemotherapy | 426 | 70.2 |
| Surgery | 303 | 49.9 | |
| Radiotherapy | 48 | 7.9 | |
| Traztuzumab | 5/43 | 11.6 | |
| Hormonal therapy | 39/53 | 73.6 | |
| Recurrence | N(303) | % | |
| Yes | 57 | 18.8 | |
| No | 236 | 77.9 | |
| Unknown | 10 | 3.3 | |
| Site of Recurrence | N(57) | % | |
| Contralateral breast | 6 | 10.5 | |
| Loco-regional | 40 | 70.6 | |
| Distant | 11 | 17.5 | |
| Survival | N(607) | % | |
| Dead | 214 | 35.3 | |
| Alive | 266 | 43.8 | |
| Unknown | 127 | 20.9 | |